CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 64 enrolled
Drug / intervention
No Interventionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04732663
NCT04732663N/ACompleted

Understanding Exertional Dyspnea and Exercise Intolerance in COVID-19

University of Alberta·observational·Posted Feb 1, 2021·Updated May 8, 2024

In Brief

An observational study evaluating No Intervention for Covid19 and Dyspnea. Completed, enrolled 64 participants across 1 site.

Detailed Summary

A novel corona virus emerged in 2019 causing Corona Virus Disease 2019 (covid-19). In one year more than 80 000 000 cases worldwide were documented. Some patients experience symptoms, specifically shortness of breath, long after the viral infection has passed. These patients are colloquially known as "Covid-19 Long-Haulers" and it is currently unknown why symptoms remain after infection. Shortness of breath and exercise intolerance may be caused by corona virus infection, covid-19 therapy, and reduced physical activity. Exercise intolerance may be due to lung, heart, blood vessel and muscle changes. During infection, the corona virus appears to cause lung blood vessel and gas exchange surface damage. Early reports show heart dysfunction, secondary to pulmonary blood vessel dysfunction or damage. Critically, no data is available on lung blood vessel function or cardiac function during exercise. Moreover, no data are available to link persistent symptoms to physiology parameters. To better understand symptom persistence in Covid-19, the investigators aim to measure exercise tolerance and heart and lung function in covid-19 survivors and compare them to covid-19 free controls.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19, Dyspnea
CountriesCanada
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedFeb 1, 2021
Enrollment StartMar 4, 2021
Primary CompletionOct 1, 2021
Study CompletionMay 6, 2024
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 5.4 years ago

Interventions

No Interventionother

Cross-sectional study, no intervention.